Trials / Recruiting
RecruitingNCT07020832
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 320 (estimated)
- Sponsor
- Apellis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegcetacoplan | Complement (C3) Inhibitor |
| OTHER | Placebo | Sterile solution of equal volume to active arm |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2027-08-01
- Completion
- 2028-08-01
- First posted
- 2025-06-13
- Last updated
- 2026-03-13
Locations
1 site across 1 country: Brazil
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07020832. Inclusion in this directory is not an endorsement.